Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ramon Alemany

Showing results (61-70 of 99) with videos related to

Pageof 10
Sort By:
Cancer Research|February 2, 2017
Oncolytic Adenoviral Delivery of an EGFR-Targeting T-cell Engager Improves Antitumor EfficacyCarlos Alberto Fajardo, Sonia Guedan, Luis Alfonso Rojas, et al.
International Journal of Cancer|November 18, 2003
Retargeting of adenoviral infection to melanoma: combining genetic ablation of native tropism with a recombinant bispecific single-chain diabody (scDb) adapter that binds to fiber knob and HMWMAADirk M Nettelbeck, Angel A Rivera, Jörg Kupsch, et al.
NAR Cancer|July 28, 2021
Transgene codon usage drives viral fitness and therapeutic efficacy in oncolytic adenovirusesEstela Núñez-Manchón, Martí Farrera-Sal, Marc Otero-Mateo, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 19, 2015
Mesenchymal Stromal Cells for Linked Delivery of Oncolytic and Apoptotic Adenoviruses to Non-small-cell Lung CancersValentina Hoyos, Francesca Del Bufalo, Shigeki Yagyu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 25, 2017
Shaping the Tumor Stroma and Sparking Immune Activation by CD40 and 4-1BB Signaling Induced by an Armed Oncolytic VirusEmma Eriksson, Ioanna Milenova, Jessica Wenthe, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 3, 2010
Minimal RB-responsive E1A promoter modification to attain potency, selectivity, and transgene-arming capacity in oncolytic adenovirusesJuan J Rojas, Sonia Guedan, Peter F Searle, et al.
Cancer Research|April 17, 2004
Conditionally replicating adenoviruses expressing short hairpin RNAs silence the expression of a target gene in cancer cellsJan E Carette, Renée M Overmeer, Frederik H E Schagen, et al.
Molecular Therapy Oncolytics|June 12, 2018
Evidence of Anti-tumoral Efficacy in an Immune Competent Setting with an iRGD-Modified Hyaluronidase-Armed Oncolytic AdenovirusAhmed Abdullah Al-Zaher, Rafael Moreno, Carlos Alberto Fajardo, et al.
Cancer Immunology Research|March 29, 2018
Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus-Driven Production of a Bispecific T-cell EngagerAnna Wing, Carlos Alberto Fajardo, Avery D Posey, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|July 19, 2014
A genetic fiber modification to achieve matrix-metalloprotease-activated infectivity of oncolytic adenovirusAnabel José, Maria Rovira-Rigau, Jeroni Luna, et al.
Pageof 10

Showing results (61-70 of 99) with videos related to

Sort By:
Pageof 10
Cancer Research|February 2, 2017
Oncolytic Adenoviral Delivery of an EGFR-Targeting T-cell Engager Improves Antitumor EfficacyCarlos Alberto Fajardo, Sonia Guedan, Luis Alfonso Rojas, et al.
International Journal of Cancer|November 18, 2003
Retargeting of adenoviral infection to melanoma: combining genetic ablation of native tropism with a recombinant bispecific single-chain diabody (scDb) adapter that binds to fiber knob and HMWMAADirk M Nettelbeck, Angel A Rivera, Jörg Kupsch, et al.
NAR Cancer|July 28, 2021
Transgene codon usage drives viral fitness and therapeutic efficacy in oncolytic adenovirusesEstela Núñez-Manchón, Martí Farrera-Sal, Marc Otero-Mateo, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 19, 2015
Mesenchymal Stromal Cells for Linked Delivery of Oncolytic and Apoptotic Adenoviruses to Non-small-cell Lung CancersValentina Hoyos, Francesca Del Bufalo, Shigeki Yagyu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 25, 2017
Shaping the Tumor Stroma and Sparking Immune Activation by CD40 and 4-1BB Signaling Induced by an Armed Oncolytic VirusEmma Eriksson, Ioanna Milenova, Jessica Wenthe, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 3, 2010
Minimal RB-responsive E1A promoter modification to attain potency, selectivity, and transgene-arming capacity in oncolytic adenovirusesJuan J Rojas, Sonia Guedan, Peter F Searle, et al.
Cancer Research|April 17, 2004
Conditionally replicating adenoviruses expressing short hairpin RNAs silence the expression of a target gene in cancer cellsJan E Carette, Renée M Overmeer, Frederik H E Schagen, et al.
Molecular Therapy Oncolytics|June 12, 2018
Evidence of Anti-tumoral Efficacy in an Immune Competent Setting with an iRGD-Modified Hyaluronidase-Armed Oncolytic AdenovirusAhmed Abdullah Al-Zaher, Rafael Moreno, Carlos Alberto Fajardo, et al.
Cancer Immunology Research|March 29, 2018
Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus-Driven Production of a Bispecific T-cell EngagerAnna Wing, Carlos Alberto Fajardo, Avery D Posey, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|July 19, 2014
A genetic fiber modification to achieve matrix-metalloprotease-activated infectivity of oncolytic adenovirusAnabel José, Maria Rovira-Rigau, Jeroni Luna, et al.
Pageof 10